- call +1-201-465-4211
- email sales@mrinsights.biz
The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.
Scope of the Report:
This report studies the Circulating Tumor Cells and Cancer Stem Cells market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Circulating Tumor Cells and Cancer Stem Cells market by product type and applications/end industries.
The global circulating tumor cells and cancer stem cells market is anticipated to grow at a rapid rate owing to development in biotechnology and biomedical engineering. According to WHO, Cancer is the leading cause of mortality and morbidity globally impacting about 14 million people annually, leading to rapid increase in research activities worldwide. Circulating tumor cells and cancer stem cells are under research for various types of cancer such as breast cancer, lung cancer, colorectal cancer, skin cancer. Government and various government bodies are taking interest and initiative to boost funds and activities which is one of the major factor driving the growth of the global circulating tumor cells and cancer stem cells market.
The global Circulating Tumor Cells and Cancer Stem Cells market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Circulating Tumor Cells and Cancer Stem Cells.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
QIAGEN Hannover
AVIVA Biosciences
Epic Sciences
ApoCell
Cynvenio Biosystems
Fluxion Biosciences
Rarecells
Janssen Diagnostics
CellTraffix
Silicon Biosystems
Advanced Cell Diagnostics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Cell Enrichment
Detection
CTC Analysis
Market Segment by Applications, can be divided into
Hospital
NSC
Medical Research Institute
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Circulating Tumor Cells and Cancer Stem Cells Market Overview
1.1 Product Overview and Scope of Circulating Tumor Cells and Cancer Stem Cells
1.2 Classification of Circulating Tumor Cells and Cancer Stem Cells by Types
1.2.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue Comparison by Types (2017-2023)
1.2.2 Global Circulating Tumor Cells and Cancer Stem Cells Revenue Market Share by Types in 2017
1.2.3 Cell Enrichment
1.2.4 Detection
1.2.5 CTC Analysis
1.3 Global Circulating Tumor Cells and Cancer Stem Cells Market by Application
1.3.1 Global Circulating Tumor Cells and Cancer Stem Cells Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 NSC
1.3.4 Medical Research Institute
1.4 Global Circulating Tumor Cells and Cancer Stem Cells Market by Regions
1.4.1 Global Circulating Tumor Cells and Cancer Stem Cells Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Circulating Tumor Cells and Cancer Stem Cells Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Circulating Tumor Cells and Cancer Stem Cells Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Circulating Tumor Cells and Cancer Stem Cells Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Circulating Tumor Cells and Cancer Stem Cells Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Circulating Tumor Cells and Cancer Stem Cells Status and Prospect (2013-2023)
1.5 Global Market Size of Circulating Tumor Cells and Cancer Stem Cells (2013-2023)
2 Manufacturers Profiles
2.1 QIAGEN Hannover
2.1.1 Business Overview
2.1.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 QIAGEN Hannover Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.2 AVIVA Biosciences
2.2.1 Business Overview
2.2.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AVIVA Biosciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.3 Epic Sciences
2.3.1 Business Overview
2.3.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Epic Sciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.4 ApoCell
2.4.1 Business Overview
2.4.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 ApoCell Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.5 Cynvenio Biosystems
2.5.1 Business Overview
2.5.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cynvenio Biosystems Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.6 Fluxion Biosciences
2.6.1 Business Overview
2.6.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Fluxion Biosciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.7 Rarecells
2.7.1 Business Overview
2.7.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Rarecells Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.8 Janssen Diagnostics
2.8.1 Business Overview
2.8.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Janssen Diagnostics Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.9 CellTraffix
2.9.1 Business Overview
2.9.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 CellTraffix Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.10 Silicon Biosystems
2.10.1 Business Overview
2.10.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Silicon Biosystems Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
2.11 Advanced Cell Diagnostics
2.11.1 Business Overview
2.11.2 Circulating Tumor Cells and Cancer Stem Cells Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Advanced Cell Diagnostics Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2016-2017)
3 Global Circulating Tumor Cells and Cancer Stem Cells Market Competition, by Players
3.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Circulating Tumor Cells and Cancer Stem Cells Players Market Share
3.2.2 Top 10 Circulating Tumor Cells and Cancer Stem Cells Players Market Share
3.3 Market Competition Trend
4 Global Circulating Tumor Cells and Cancer Stem Cells Market Size by Regions
4.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue and Market Share by Regions
4.2 North America Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
4.3 Europe Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
4.5 South America Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
5 North America Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries
5.1 North America Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries (2013-2018)
5.2 USA Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
5.3 Canada Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
5.4 Mexico Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
6 Europe Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries
6.1 Europe Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries (2013-2018)
6.2 Germany Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
6.3 UK Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
6.4 France Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
6.5 Russia Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
6.6 Italy Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries
7.1 Asia-Pacific Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries (2013-2018)
7.2 China Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
7.3 Japan Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
7.4 Korea Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
7.5 India Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
8 South America Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries
8.1 South America Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries (2013-2018)
8.2 Brazil Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
8.3 Argentina Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
8.4 Colombia Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Circulating Tumor Cells and Cancer Stem Cells by Countries
9.1 Middle East and Africa Circulating Tumor Cells and Cancer Stem Cells Revenue by Countries (2013-2018)
9.2 Saudi Arabia Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
9.3 UAE Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
9.4 Egypt Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
9.5 Nigeria Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
9.6 South Africa Circulating Tumor Cells and Cancer Stem Cells Revenue and Growth Rate (2013-2018)
10 Global Circulating Tumor Cells and Cancer Stem Cells Market Segment by Type
10.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue and Market Share by Type (2013-2018)
10.2 Global Circulating Tumor Cells and Cancer Stem Cells Market Forecast by Type (2018-2023)
10.3 Cell Enrichment Revenue Growth Rate (2013-2023)
10.4 Detection Revenue Growth Rate (2013-2023)
10.5 CTC Analysis Revenue Growth Rate (2013-2023)
11 Global Circulating Tumor Cells and Cancer Stem Cells Market Segment by Application
11.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue Market Share by Application (2013-2018)
11.2 Circulating Tumor Cells and Cancer Stem Cells Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 NSC Revenue Growth (2013-2018)
11.5 Medical Research Institute Revenue Growth (2013-2018)
12 Global Circulating Tumor Cells and Cancer Stem Cells Market Size Forecast (2018-2023)
12.1 Global Circulating Tumor Cells and Cancer Stem Cells Market Size Forecast (2018-2023)
12.2 Global Circulating Tumor Cells and Cancer Stem Cells Market Forecast by Regions (2018-2023)
12.3 North America Circulating Tumor Cells and Cancer Stem Cells Revenue Market Forecast (2018-2023)
12.4 Europe Circulating Tumor Cells and Cancer Stem Cells Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Circulating Tumor Cells and Cancer Stem Cells Revenue Market Forecast (2018-2023)
12.6 South America Circulating Tumor Cells and Cancer Stem Cells Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Circulating Tumor Cells and Cancer Stem Cells Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Circulating Tumor Cells and Cancer Stem Cells Picture
Table Product Specifications of Circulating Tumor Cells and Cancer Stem Cells
Table Global Circulating Tumor Ce
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
